CERo Therapeutics Holdings, Inc. (CERO)
After hours:
| Previous Close | 0.3596 |
| Open | 0.3480 |
| Bid | 0.3700 x 200 |
| Ask | 0.3800 x 100 |
| Day's Range | 0.3400 - 0.4133 |
| 52 Week Range | 0.3300 - 12.8000 |
| Volume | |
| Avg. Volume | 1,160,333 |
| Market Cap | 5.722M |
| Beta (5Y Monthly) | -0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236
Company anticipates near term filing of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announced it successfully executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The completion of multiple manufacturing runs i
- ACCESSWIRE
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life. Source: PexelsThe first CAR T-cell therapy ...
- GlobeNewswire
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the successful completion of toxicology studies for its lead compound, CER-1236. The toxicology studies w
